Livforsakringsbolaget Skandia Omsesidigt Boosts Holdings in Eli Lilly and Company $LLY

Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 37.5% in the first quarter, HoldingsChannel reports. The fund owned 41,040 shares of the company’s stock after buying an additional 11,200 shares during the quarter. Eli Lilly and Company makes up about 1.5% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 12th largest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Eli Lilly and Company were worth $37,747,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $30,000. Finally, Maseco LLP grew its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Morgan Stanley raised their price objective on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. UBS Group raised their price target on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,271.93.

Eli Lilly and Company Stock Down 2.3%

Shares of Eli Lilly and Company stock opened at $1,154.27 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.09 trillion, a P/E ratio of 41.00, a P/E/G ratio of 1.44 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The business has a 50-day moving average price of $1,106.93 and a 200 day moving average price of $1,034.58.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.5 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly won full FDA approval for selpercatinib in solid tumors, a regulatory win that could support future oncology revenue and reinforces the strength of Lilly’s pipeline. Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
• Positive Sentiment: Wall Street sentiment remains constructive, with Guggenheim raising its price target on Lilly and maintaining a buy rating, while other recent reports highlighted bullish analyst views and momentum around the company’s pipeline. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with articles noting that its weight-loss drugs now account for a very large share of revenue, underscoring how central that growth engine remains for the stock. Here’s How Much Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
• Neutral Sentiment: Lilly has been presenting new Kisunla data at the Alzheimer’s Association International Conference, which keeps attention on its dementia pipeline but does not yet appear to have delivered a clear market-moving surprise. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Neutral Sentiment: Commentary on whether Lilly’s shares can climb much higher has added to trading interest, but this is largely market speculation rather than a new fundamental catalyst. Is Lilly Stock On Track To Hit $2,090?
• Negative Sentiment: Despite the positive pipeline and analyst backdrop, traders are reacting to signs of weakness in LLY shares versus the broader market, suggesting some profit-taking or rotation out of the name. Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: One article flagged a “disturbing trend” in the billion-dollar obesity-drug market as Lilly prepares to roll out its new weight-loss pill, hinting at rising scrutiny of competition and execution risk in its most important growth category. Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.